Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.
1. A pharmaceutical combination product comprising:
a) 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide in an amount of about 62.5 mcg/dose, in the form of a dry powder; and
b) 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol triphenylacetate, in an amount of about 25 mcg/dose, in the form of a dry powder,
wherein said pharmaceutical combination product is suitable for once-daily administration, and compounds a) and b) are presented in a form adapted for simultaneous administration.
2. The product according to claim 1 , in a dry powder composition form suitable for administration by inhalation via a medicament dispenser, selected from the group consisting of a reservoir dry powder inhaler, a unit-dose dry powder inhaler, and a pre-metered multi-dose dry powder inhaler.
3. The product according to claim 2 , wherein 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide and 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol triphenylacetate are separate dry powder compositions or admixed as a single dry powder composition.
4. The product according to claim 3 , further comprising a carrier which comprises lactose.
5. The product according to claim 3 , further comprising a ternary agent.
6. The product according to claim 5 , further comprising a carrier; and wherein the ternary agent comprises magnesium stearate, wherein said magnesium stearate is present in an amount of about 0.6% w/w in the composition of 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide, and/or an amount of about 1.0% w/w in a composition of 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol triphenylacetate.
7. The product according to claim 3 , wherein said separate compositions are in unit dose form selected from the group consisting of a capsule, a cartridge or a blister.
8. The product according to claim 1 , further comprising 6α,9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid S-fluoromethyl ester (fluticasone furoate).
9. The product according to claim 8 , wherein 6α,9αdifluoro-17α-[(2-furanylcarbonyl)oxy]-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid S-fluoromethyl ester (fluticasone furoate) is present in an amount of about 100 mcg/dose.
10. A pharmaceutical combination product comprising:
a) a first dry powder composition comprising 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide, in an amount of about 62.5 mcg/dose; lactose; and magnesium stearate in an amount of about 0.6% w/w of said first dry powder composition; and
b) a second dry powder composition comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol triphenylacetate, in an amount of about 25 mcg/dose; lactose, and; magnesium stearate in an amount of about 1.0% w/w of said second dry powder composition;
wherein said pharmaceutical combination product is suitable for once-daily administration, and
wherein the first and second dry powder compositions are configured for simultaneous administration.
11. The product according to claim 10 , wherein the first and second dry powder compositions are presented in a form suitable for administration by inhalation via a medicament dispenser, said medicament dispenser being selected from the group consisting of a reservoir dry powder inhaler, a unit-dose dry powder inhaler, and a pre-metered multi-dose dry powder inhaler.
12. A pharmaceutical combination product comprising:
a) 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide in an amount of 62.5 mcg/dose, in the form of a dry powder;
b) 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol triphenylacetate, in an amount of 25 mcg/dose, in the form of a dry powder,
c) 6α,9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid S-fluoromethyl ester (fluticasone furoate), in an amount of 100 mcg/dose, in the form of a dry powder,
d) carrier excipient, and
e) ternary agent, wherein said pharmaceutical combination product is suitable for once-daily administration, and compounds a), b) and c) are presented in a form adapted for simultaneous administration.
13. The pharmaceutical combination product of claim 12 , wherein:
a first dry powder composition comprises an admixture of compound a), compound b), carrier excipient d), and ternary agent e); and
a second dry powder compositions comprises an admixture of compound c) and carrier excipient d).
14. The pharmaceutical combination product of claim 12 , wherein the carrier excipient in said first and second dry powder compositions is lactose monohydrate, and the ternary agent in said first dry powder composition is magnesium stearate.
15. The pharmaceutical combination product of claim 13 , wherein said first and second dry powder compositions are in unit dose form and in the form of a capsule, a cartridge or a blister.
16. The pharmaceutical combination product according to claim 12 , in a dry powder composition form suitable for administration by inhalation via a medicament dispenser selected from a reservoir dry powder inhaler, a unit-dose dry powder inhaler, or a pre-metered multi-dose dry powder inhaler.
17. The pharmaceutical combination product according to claim 15 , in a dry powder composition form suitable for administration by inhalation via a medicament dispenser selected from a unit-dose dry powder inhaler, or a pre-metered multi-dose dry powder inhaler.